Keystone Financial Group (Kentucky)’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $453K | Sell |
8,206
-871
| -10% | -$47.2K | 0.03% | 314 |
|
|
2025
Q4 | $445K | Sell |
9,077
-11
| -0.1% | -$513 | 0.03% | 275 |
|
|
2025
Q3 | $392K | Buy |
9,088
+22
| +0.2% | +$859 | 0.03% | 274 |
|
|
2025
Q2 | $348K | Sell |
9,066
-28
| -0.3% | -$1.07K | 0.03% | 286 |
|
|
2025
Q1 | $352K | Sell |
9,094
-288
| -3% | -$10.5K | 0.04% | 262 |
|
|
2024
Q4 | $317K | Sell |
9,382
-137
| -1% | -$4.93K | 0.03% | 285 |
|
|
2024
Q3 | $389K | Buy |
9,519
+482
| +5% | +$19.7K | 0.05% | 236 |
|
|
2024
Q2 | $348K | Sell |
9,037
-194
| -2% | -$8.16K | 0.12% | 112 |
|
|
2024
Q1 | $396K | Buy |
9,231
+43
| +0.5% | +$1.77K | 0.06% | 210 |
|
|
2023
Q4 | $341K | Sell |
9,188
-2,021
| -18% | -$72.6K | 0.06% | 197 |
|
|
2023
Q3 | $406K | Buy |
11,209
+1,608
| +17% | +$57.1K | 0.07% | 178 |
|
|
2023
Q2 | $342K | Buy |
+9,601
| New | +$344K | 0.06% | 198 |
|
|
2022
Q4 | $350K | Buy |
9,971
+466
| +5% | +$15.5K | 0.07% | 185 |
|
|
2022
Q3 | $280K | Buy |
9,505
+973
| +11% | +$36.9K | 0.06% | 211 |
|
|
2022
Q2 | $464K | Sell |
8,532
-997
| -10% | -$55K | 0.09% | 157 |
|
|
2022
Q1 | $519K | Sell |
9,529
-9
| -0.1% | -$489 | 0.09% | 153 |
|
|
2021
Q4 | $526K | Sell |
9,538
-21
| -0.2% | -$1.09K | 0.09% | 160 |
|
|
2021
Q3 | $457K | Buy |
9,559
+19
| +0.2% | +$954 | 0.08% | 172 |
|
|
2021
Q2 | $475K | Buy |
9,540
+326
| +4% | +$15.7K | 0.09% | 162 |
|
|
2021
Q1 | $411K | Buy |
9,214
+1,998
| +28% | +$90.7K | 0.08% | 173 |
|
|
2020
Q4 | $332K | Buy |
7,216
+210
| +3% | +$9.65K | 0.07% | 184 |
|
|
2020
Q3 | $330K | Sell |
7,006
-420
| -6% | -$21K | 0.08% | 169 |
|
|
2020
Q2 | $379K | Sell |
7,426
-23
| -0.3% | -$1.18K | 0.1% | 149 |
|
|
2020
Q1 | $353K | Buy |
7,449
+1,103
| +17% | +$58.8K | 0.12% | 136 |
|
|
2019
Q4 | $373K | Buy |
6,346
+8
| +0.1% | +$445 | 0.1% | 153 |
|
|
2019
Q3 | $338K | Buy |
6,338
+1,269
| +25% | +$65.3K | 0.1% | 159 |
|
|
2019
Q2 | $254K | Sell |
5,069
-216
| -4% | -$10.8K | 0.08% | 186 |
|
|
2019
Q1 | $276K | Buy |
+5,285
| New | +$264K | 0.1% | 168 |
|
|
2018
Q4 | – | Sell |
-4,738
| Closed | -$237K | – | 187 |
|
|
2018
Q3 | $237K | Buy |
4,738
+4
| +0.1% | +$203 | 0.1% | 169 |
|
|
2018
Q2 | $237K | Buy |
4,734
+3
| +0.1% | +$151 | 0.13% | 142 |
|
|
2018
Q1 | $230K | Buy |
4,731
+261
| +6% | +$12.2K | 0.13% | 135 |
|
|
2017
Q4 | $209K | Buy |
+4,470
| New | +$206K | 0.13% | 120 |
|
Other funds holding GSK
JEST
Keystone Financial Group (Kentucky)'s GSK Position: Q1 2026 in Review
Keystone Financial Group (Kentucky) reduced its GSK (GSK) stake by 9.6% in Q1 2026, selling an estimated $47.2K and leaving 8,206 shares worth $453K. The position accounts for 0.03% of the portfolio, ranked #314.
Keystone Financial Group (Kentucky) first reported a position in GSK in Q4 2017 and has held it in 32 quarters since. The position peaked at $526K in Q4 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Keystone Financial Group (Kentucky) held 8,206 shares of GSK worth $453K as of Q1 2026.
- Keystone Financial Group (Kentucky) sold 871 GSK shares in Q1 2026, an estimated $47.2K.
- GSK made up 0.03% of Keystone Financial Group (Kentucky)'s portfolio in Q1 2026, its #314 holding.
- Keystone Financial Group (Kentucky) first reported a position in GSK in Q4 2017 and has held it in 32 quarters since.
- Keystone Financial Group (Kentucky)'s GSK position peaked at $526K in Q4 2021.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Keystone Financial Group (Kentucky)'s 13F filing for Q1 2026, filed 13 May 2026.